ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: This is in contrast to the combination strategies that use different inhibitors to target the same molecule, such as the simultaneous use of ATP-site inhibitors and allosteric inhibitors of BCR-ABL1 fusion kinase in CML (53, 77).